Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma †
Titel:
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma †
Auteur:
Mita, M.M. Poplin, E. Britten, C.D. Tap, W.D. Rubin, E.H. Scott, B.B. Berk, L. Rivera, V.M. Loewy, J.W. Dodion, P. Haluska, F. Sarantopoulos, J. Mita, A. Tolcher, A.